The press release also contained forward-looking statements, cautioning that these are not guarantees and are subject to risks, uncertainties, and other factors that could cause actual results to differ from expectations.

The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled

Moderna on Friday said it received approval for supplying its Spikevax Covid-19 vaccine to the European Union, Norway and North Macedonia following a tender process. Under the agreement, 17 participating countries could order an updated version of the biotech company's mRNA Covid-19 vaccine for up to four years.

Moderna won an agreement for its Covid vaccines in Europe on Friday, but Moderna stock reversed its early gains.